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Abstract
Background—Interpretation of longitudinal information about lung function decline from 
middle to older age has been limited by loss to follow-up that may be correlated with baseline lung 
function or the rate of decline. We conducted these analyses to estimate age-related decline in lung 
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function across groups of race, sex, and smoking status while accounting for dropout from the 
Atherosclerosis Risk in Communities Study.
Methods—We analyzed data from 13,896 black and white participants, aged 45–64 years at the 
1987–1989 baseline clinical examination. Using spirometry data collected at baseline and two 
follow-up visits, we estimated annual population-averaged mean changes in forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC) by race, sex, and smoking status 
using inverse-probability-weighted independence estimating equations conditioning-on-being-
alive.
Results—Estimated rates of FEV1 decline estimated using inverse-probability-weighted 
independence estimating equations conditioning on being alive were higher among white than 
black participants at age 45 years (e.g., male never smokers: black: −29.5 ml/year; white: −51.9 
ml/year), but higher among black than white participants by age 75 (black: −51.2 ml/year; white: 
−26). Observed differences by race were more pronounced among men than among women. By 
smoking status, FEV1 declines were larger among current than former or never smokers at age 45 
across all categories of race and sex. By age 60, FEV1 decline was larger among former and never 
than current smokers. Estimated annual declines generated using unweighted generalized 
estimating equations were smaller for current smokers at younger ages in all four groups of race 
and sex compared with results from weighted analyses that accounted for attrition.
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1. Introduction
Low measures of pulmonary function are diagnostic for chronic obstructive pulmonary 
disease (COPD) and characteristic of other lung conditions. Longitudinal research provides 
evidence that spirometric measures of pulmonary function also predict the development of 
arrhythmias, risk of coronary heart disease, heart failure, cognitive decline, and mortality in 
the general population, even among individuals without known lung disease and among non-
smokers [1–8]. Because of these associations, however, pulmonary function may affect 
continued participation in the very prospective studies used to evaluate trajectories of lung 
function. If baseline lung function affects continued participation, then this potential source 
of bias may interfere with the interpretation of results on rates of lung function decline over 
time [9].
A recent study of the association between smoking and cognitive decline attempted to 
account for loss to follow-up that may depend on baseline levels of both smoking and 
cognitive function [10]. Similar methods have not been applied to the study of decline of 
lung function with age. To date, epidemiologic studies of rates of lung function decline have 
focused largely on describing discrepancies between estimates generated using cross-
sectional versus longitudinal data [11–13], assessing modification of the effects of smoking 
on lung function decline [14–17], and evaluating associations between genetic variation and 
lung function decline [18,19]. While one study examined lung function declines leading to 
COPD [20] and several have examined differences in lung function decline by race, sex, and 
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smoking status [12,13,17], longitudinal studies have not generally accounted for the 
potential influences of dropout during study follow-up. Results from such longitudinal 
studies, based on participants healthy enough to continue participating, may underestimate 
rates of lung function decline in the target population.
In longitudinal studies of lung function, individuals who do not continue to participate may 
do so due to death during the study follow-up or withdrawal (i.e., dropout) from the study 
for reasons other than death. While existing literature cautions against making inferences as 
if death did not occur by extrapolating observations beyond death [21,22], new statistical 
methods are now available to address loss to follow-up–that is, study attrition–among 
individuals who were alive at the time of the follow-up observation, but did not continue to 
participate [22,23]. Considering the documented associations between lung function and 
both morbidity and mortality [1–8], distinguishing between attrition due to death and 
dropout for reasons other death could plausibly influence estimates of lung function decline. 
By taking into account non-death loss to follow-up, new statistical methods may improve 
estimation of lung function decline generated from longitudinal studies [22,23].
The Atherosclerosis Risk in Communities (ARIC) study provides an opportunity to extend 
our understanding about lung function decline by evaluating variation in patterns of age-
related changes in lung function in a large, population-based cohort of black and white 
adults in the United States. We used data from three clinical examinations spanning 
approximately 25 years to estimate rates of decline in forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) across groups of race, sex, and cigarette 
smoking status. Our analyses examined quantitative changes in pulmonary function, rather 
than diagnoses of chronic obstructive pulmonary disease or other conditions. Because low 
measures of FVC and FEV1 are risk factors for morbidity and mortality in the general 
population, even among individuals with measures in the normal range [24,25], quantitative 
changes in FVC and FEV1 are valuable metrics of pulmonary health regardless of whether 
such changes reach a threshold for impairment. We accounted for non-participation in 
follow-up visits using inverse-probability-weighted independence estimating equations with 
population-averaged linear models for regression conditioning-on-being-alive [22,23].
2. Methods
2.1. Study population
The ARIC study is a prospective cohort study designed to evaluate the etiology of 
atherosclerosis and its clinical sequelae in a general population based sample of adults [26]. 
Men and women, aged 45–64 years, were recruited and enrolled from four U.S. 
communities: Forsyth County, North Carolina; Jackson, Mississippi; suburbs of 
Minneapolis, Minnesota; and Washington County, Maryland. Initial examination of the 
cohort took place in 1987–1989 (‘visit 1’, n = 15,792), when participants responded to 
health-related questionnaires and completed a clinical examination. Follow-up examinations 
occurred in 1990–1992 (‘visit 2’, n = 14,348; 93% of those still alive) when participants 
were 48–67 years of age, 1993–1995 (‘visit 3’), 1996–1998 (‘visit 4’), and 2011–2013 
(‘visit 5’, n = 6538; 65% of those still alive) when participants were 65–90 years of age. Of 
the 15,792 adults who completed visit 1, 13,896 were included in our final analysis after 
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sequentially excluding participants based on the following criteria: data use restricted by 
participant consent (n = 41), race other than black or white (n = 48), black participants 
recruited from suburbs of Minneapolis, Minnesota or Washington County, Maryland (n = 
54), incomplete spirometry at visit 1 (n = 138), errors in recording spirometry data (n = 
182), and inadequate participant effort (n = 1433). The study protocol and instruments were 
approved by institutional review boards at each of the four participating exam sites and the 
data coordinating center, and all participants provided written informed consent. The 
analyses presented here were exempted from institutional review board review at the Centers 
for Disease Control and Prevention.
2.2. Spirometry
FEV1 and FVC were measured at visits 1 and 2 using Collins Survey II water-seal 
spirometers (Warren E. Collins Inc., Braintree, MA) and at visit 5 using SensorMedics 
model 1022 dry rolling seal spirometers (OMI, Houston, TX). At each visit, spirometry 
testing protocols were standardized across the four ARIC field centers, calibration checks 
were performed daily, and the standardization of data collection and management was 
coordinated across field centers by a single pulmonary function reading center. For the 
present analysis, we used two spirometry measurements: FEV1 and FVC, both in milliliters 
(ml). At each visit, we selected each participant's best FEV1 and FVC of three acceptable 
maneuvers, based on the centralized expert review.
2.3. Covariates
Age, race, and sex were self-reported and height was measured at the visit 1 exam. Body 
mass index, cigarette smoking status, history of asthma, and history of chronic lung diseases 
other than asthma were defined and updated at visits 1, 2, and 5, respectively, using 
information collected at each of the visits and via annual follow-up telephone calls.
2.4. Statistical analysis
To estimate FEV1 and FVC at age 45 years, the FEV1/FVC ratio at age 45 years, and annual 
changes in FEV1 and FVC across categories of race, sex, and smoking status, we used 
inverse-probability-weighted independence estimating equations with population-averaged 
linear models for regression conditioning-on-being-alive [22,23,27]. The statistical models 
are described in detail in the online supplement.
Because the statistical models included a non-linear specification of time, our results 
generated annual changes in FEV1 and FVC that are not constant over the follow-up period. 
That is, the estimated annual changes are not constant across the range of ages included in 
our analysis and therefore cannot be summarized with a single set of race-, sex-, and 
smoking status-specific coefficients. To most clearly present these results, we calculated 
population-averaged mean estimates of FEV1 and FVC, with 95% confidence intervals (CIs) 
at age 45 years to represent baseline measures of lung function for each of the 12 categories 
of race, sex, and smoking status and present estimated annual declines in FEV1 and FVC at 
the a priori selected ages of 45, 60, and 75 years. Estimated annual declines at age 45 years 
were calculated as the change from ages 45 to 46; estimated annual declines at age 60 years 
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were calculated as the change from ages 60 to 61, and estimated annual declines at age 75 
years were calculated as the change from ages 75–76 years.
For comparison, we also estimated annual declines in FEV1 and FVC in models fitted using 
unweighted generalized estimating equations (GEE) with independence working correlation 
matrices. These models were specified identically to the regression conditioning-on-being-
alive models. Empirical sandwich variance estimators were used for both weighted and 
unweighted modeling approaches.
3. Results
3.1. Characteristics of the study population
Characteristics at visit 1 of the 13,896 participants in the analysis are shown in Table 1. 
Participant dropouts and deaths that occurred in the follow-up periods between visits 1, 2, 
and 5, the visits at which spirometry was conducted, are shown in Table S1 in the online 
supplement. At visit 1, the prevalence of asthma was 6.4% and the prevalence of other 
chronic obstructive lung diseases was 5.2%. Participants identified as former smokers or 
never smokers at visit 1 largely maintained that same smoking status throughout follow-up, 
with 95.2% of former smokers and 88.9% of never smokers maintaining their smoking status 
through visits 2 and 5. For traits that changed over time, characteristics at visit 5 are shown 
in Table S2.
3.2. Lung function at age 45 years
Adjusted population-averaged estimates of FEV1, FVC, and the FEV1/FVC ratio at age 45 
were each lower for current smokers than for former and never smokers across all categories 
of race and sex (Table 2). Estimates of both FEV1 and FVC at age 45 were lower among 
black than white participants within categories of sex and smoking status and among women 
than men within categories of race and smoking status. Within categories of smoking status, 
FEV1/FVC ratios at age 45 years were largely similar across categories of race and sex.
3.3. Lung function decline by age, race, and sex
As expected, predicted values of FEV1 and FVC declined with advancing age (Fig. 1). 
Broadly speaking, estimated rates of FEV1 decline varied by race and were higher among 
white than black participants at age 45 years (e.g., among male never smokers: black: −29.5 
ml/year [95% CI: −43.9, −15.0]; white: −51.9 ml/year [95% CI: −58.9, −44.8]), but higher 
among black than white participants by age 75 years (black: −51.2 ml/year [95% CI: −73.3, 
−29.2]; white: -26.6 ml/year [95% CI: −37.4, −15.7]), though 95% confidence intervals of 
the estimates largely overlap (Table 3). FVC declined similarly to FEV1 at age 45 years 
(e.g., among male never smokers: black: −45.0 [95% CI: −62.9, −27.0]; white: −66.8 [95% 
CI: −74.7, -59.0)] and at age 75 years (black: −33.3 [95% CI: −59.5, −7.1]; white: −18.3 
[95% CI: −30.8, −5.8]). These observed differences in estimated rates of decline by race 
were more pronounced among men than among women.
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3.4. Lung function decline by smoking status
By smoking status, estimated rates of FEV1 decline were larger among current smokers than 
former or never smokers at age 45 years across all categories of race and sex (Table 3). By 
age 60, FEV1 decline was larger among former and never smokers than among current 
smokers across all categories of race and sex. At age 75 years, the small number of current 
smokers in all groups resulted in FEV1 declines that were imprecise. In fact, for current 
smokers, changes in both FEV1 and FVC at ages older than 75 years were imprecise and we 
opted not to present them in Fig. 1. With increasing age and within categories of race and 
sex, FEV1 decline among former and never smokers attenuated among white men and 
women, whereas it remained relatively constant among black women and increased among 
black men.
3.5. Comparison of results generated using inverse-probability-weighted regression 
conditioning-on-being-alive and unweighted GEE models
Regression coefficients for the inverse-probability-weighted regression conditioning-on-
being-alive models used to generate estimates shown in Fig. 1 and Tables 2–4 are shown in 
Tables S3 and S4, in the online supplement. Estimates of lung function at age 45 years 
generated using unweighted GEE (Tables S5, in the online supplement) were similar in 
magnitude and precision to those generated in our main analysis. In contrast, the annual 
declines in FEV1 and FVC generated using unweighted GEE were smaller for current 
smokers at younger ages in all four groups of race and sex compared with results from 
weighted analyses that accounted for attrition. For example, for FEV1, the rate of change in 
45 year-old, white, male, current smokers was −59.6 ml/year in unweighted analyses (Table 
4) versus −67.0 ml/year in analyses conducted using inverse-probability-weighted regression 
conditioning-on-being-alive (Table 3). A similar pattern was observed for FVC. Differences 
between the unweighted and weighted methods attenuated by age 60 years. At age 75 years, 
by which time substantial attrition of current smokers had occurred, estimates generated 
using both methods were correspondingly unstable.
4. Discussion
Using approximately 25 years of follow-up information, we estimated annual population-
averaged changes in FEV1 and FVC within each category of race, sex, and smoking status. 
Our analyses generated patterns of declines in FEV1 and FVC that varied notably by 
smoking status and age, with largest declines at younger ages among current smokers and at 
older ages among former and never smokers. Despite the methods we applied to account for 
the decline in study participation over time this finding may be a function of the lower 
baseline FEV1 values among current smokers than among former or never smokers or 
differences between smokers who survived to old age and other smokers. Our analyses also 
generated differences in estimated rates of decline by race; declines were higher among 
white than black participants at age 45 years, but higher among black than white participants 
by age 75. Differences observed by race were more pronounced among men than among 
women.
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Two notable strengths of our study are the approximately 25 years of follow-up information 
available and the statistical approach we applied to account for attrition during the lengthy 
follow-up period. Broadly speaking, previous studies of lung function decline have not 
implemented formal statistical methods to account for attrition. Previous studies of other 
outcomes have handled attrition using different methods [28,29]. For example, under 
attrition missing-at-random assumptions, longitudinal random effects [30] and traditional 
inverse-probability-weighted regression [31] approaches have addressed the potential bias 
resulting from the diminished representativeness of the study population at later visits 
through specification of the intra-subject correlation structure or the use of weights derived 
from a model that does not distinguish between sources of attrition. In a refinement of the 
latter approach, Weuve et al. [10] derived weights from inverse-probability-weighted 
regression by joining results from separate models for death and dropout, allowing for 
different mechanisms of death and dropout, and thus weighting the data such that the study 
population at later visits more closely represents the original study population. Making 
inferences as if death did not occur and, as a result, extrapolating health metrics beyond 
death have been noted as important limitations of these approaches [21,22].
In contrast, the approach we applied assumes that the study population is continuously re-
defined by death and attempts to estimate lung function decline over time, conditioning on 
being alive (and therefore eligible for continued participation). Using this method, we 
generated weights based on predicted probabilities of each participant continuing to 
participate in the ARIC study conditioning on his/her being alive. We then applied the 
predicted probabilities to up-weight the contribution of participants with demographic and 
health-related characteristics of those not observed due to non-death dropout. If dropout 
from the ARIC study were differentially associated with lung function, then we expect that 
applying these methods would reduce the underestimation of lung function decline. Indeed, 
comparing results generated using this modeling strategy to those generated using 
unweighted GEE provides evidence that unweighted GEE models resulted in estimates of 
lung function decline that were smaller in magnitude, though 95% CIs for estimates 
generated using the two methods largely overlapped. Due to the methods we applied, our 
results are presented as population-averaged estimates and cannot be used to draw 
conclusions about individual-level lung function declines. Overall, the results presented here 
suggest that these novel methods are a valuable analytic improvement in estimating lung 
function decline in long follow-up studies.
Comparing our results to previously published age-related rates of lung function decline is 
not straight-forward. Because we regressed FEV1 and FVC on an array of covariates that 
included quadratic terms for follow-up time, the final estimated annual rates of decline 
varied non-linearly with age. To simplify the presentation of our results, we selected a priori 
three ages for which to present point estimates of the estimated annual rates of decline: ages 
45, 60, and 75 years. In light of previous research reporting higher rates of lung function 
decline among smokers than among non-smokers [13,15,32], our finding that within 
categories of race and sex, annual declines in both FEV1 and FVC were greater among 
current smokers than former smokers and never smokers at younger ages, but greater among 
former smokers and never smokers than current smokers at older ages, is novel. Better 
measures of health among current smokers than among former and never smokers, such as 
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the estimated annual declines we report at older ages, is characteristic of the effect of 
selection bias described as the ‘healthy smoker effect’ [33]. For comparison with a study 
conducted in a population ranging in age from 19 to 70 years that did not estimate declines 
at different ages, overall rates of annual decline over 13 years of follow-up were greater 
among smokers (men: −59.8 ml/year; women:−42.2 ml/year) than among non-smokers 
(men: −45.8 ml/year; women: −38.6 ml/year) [13]. From a study conducted among lifetime 
non-smokers, Ware et al. (1990) reported an age-related acceleration of the annual decline in 
FEV1 among both men and women [12]. Together, these findings provide evidence of 
variation in longitudinal FEV1 decline by sex and smoking status, but did not account for the 
extent to which loss to follow-up due to death, illness, and dropout affected the magnitude of 
or variation in the observed declines. In a recent meta-analysis of 16 longitudinal studies, the 
combined estimate for FEV1 decline was −26.9, −29.2 and −35.7 ml/year in never, former, 
and persistent smokers, respectively [32]. Most recently, Lange et al. reported on trajectories 
in lung function in three cohorts and reported declines in FEV1 ranging from −19 ml/year in 
the Lovelace Smokers Cohort to −25 ml/year in the Copenhagen City Heart Study [20]. In 
our study, results from models that accounted for attrition for reasons other than death and 
results from GEE models that did not differed most notably among current smokers at the 
youngest ages. Given the differential loss to follow-up among smokers, this finding may not 
be unexpected, since rapid decline in lung function rendered smokers underrepresented at 
our last follow-up visit, as shown by the comparison of population characteristics at baseline 
(Table 1) versus at visit 5 (Table S2). Indeed, weights used in our analyses did not take into 
account the increased mortality among smokers (Table S1) and, because pulmonary function 
testing was not included in clinic exams 3 and 4, we are unable to draw conclusions about 
changes in lung function, particularly among younger smokers, that may have been detected 
at those visits.
Between clinical examinations at study visits 2 and 5, there were changes in spirometry 
equipment. Variability in spirometry measurements collected using different devices has 
been described [34], however, side-by-side comparisons that would allow us to assess the 
validity or precision of the spirometry measurements across visits were not available for this 
analysis. To improve the internal validity of the spirometry data, Collins Survey II 
spirometers were used at all four field centers at visits 1 and 2, calibration checks were 
performed daily, and the standardization of data collection and management was overseen by 
a single pulmonary function reading center. At visit 5, all spirometry was conducted using 
SensorMedics spirometers and quality control was again coordinated across field centers. 
For all four field centers, quality assurance methods included training and practice for all 
technicians performing spirometry testing, review of spirometry tests performed, and 
feedback about the quality of the testing performed. The value of such practical training for 
spirometry technicians is well-described [35]. Changes in the spirometry equipment over 
time are not expected to have affected estimates of lung function decline differentially across 
groups of race, sex, or smoking status. Nonetheless, because our group-specific estimates of 
lung function decline pertain to the cohort of ARIC participants who were aged 45–64 years 
at the baseline visit, our models were adjusted for period effects that may have accounted for 
changes in spirometry equipment over time. The role of period effects in our statistical 
models is further described in the online supplement.
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Our analyses did not take into account secondhand tobacco smoke and occupational 
exposures or other exposures that may affect lung function over time. The analyses also did 
not take into account pack-years of cigarette smoking or the duration of smoking prior to 
visit 1, nor did they take into account precise quit dates among participants who began the 
study as current smokers and transitioned to former smokers during follow-up. If these or 
other factors that may affect lung function over time are distributed unequally across 
categories of race, sex, or smoking status, then our results may have been affected by 
residual confounding. By including time-varying information about body mass index, our 
analyses did account for changes in participant body weight over time. Our models did not 
evaluate whether the observed declines in lung function with increasing weight were 
equivalent in men and women.
In summary, we applied inverse-probability-weighted regression conditioning-on-being-alive 
methods to generate estimates of age-related declines in FEV1 and FVC across categories of 
race, sex, and smoking status, while accounting for non-death dropout during approximately 
25-years of follow-up of the ARIC study population. Our findings demonstrate a consistent 
pattern of decline in FEV1 and FVC over time in all categories of race, sex, and smoking 
status. Declines varied most notably by smoking status and age, with largest declines 
occurring among current smokers at the youngest ages. Compared with the weighted 
methods we used, unweighted methods not accounting for attrition underestimated declines 
in lung function among current smokers at younger ages. Thus, our findings suggest that 
using statistical methods to account for differential dropout may be worthwhile when 
evaluating decline in lung function over a lengthy follow-up period. Since spirometric 
measures of pulmonary function are diagnostic for COPD and predictive of cardiovascular 
morbidity and mortality in the general population, our estimates of lung function decline 
provide valuable information about the extent to which race, sex, and smoking status may 
influence trajectories of lung function decline during middle age and later in life. Additional 
improvements in our understanding of these and other risk factors for lung function decline 
may continue to improve our insight into the mechanisms by which lung function influences 
illness and predicts mortality.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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GEE generalized estimating equations
ml milliliters
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Fig. 1. 
Predicted FEV1 (panels A-D) and FVC (panels E-H) among current smokers (dashed black 
line), former smokers (solid black line), and never smokers (dotted gray line) for the cohort 
of ARIC study participants aged 45–64 years at baseline, by race and sex.
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Table 1
Demographic and health-related characteristics of the final study sample at visit 1: the ARIC Study.
All Participants Race
Black White
No. (%)a No. (%)a No. (%)a
Total 13,896 (100.0) 3428 (24.7)b 10,468 (75.3)b
Study center
 Forsyth County, NC 3627 (26.1) 383 (11.2) 3244 (31.0)
 Jackson, MS 3045 (21.9) 3045 (88.8) –
 Suburbs of Minneapolis, MN 3655 (26.3) – 3655 (34.9)
Washington County, MD 3569 (25.7) – 3569 (34.1)
Demographic characteristics
 Age
  45–49 3768 (27.1) 1094 (31.9) 2674 (25.5)
  50–54 3639 (26.2) 926 (27.0) 2713 (25.9)
  55–59 3362 (24.2) 732 (21.4) 2630 (25.1)
  60–64 3127 (22.5) 676 (19.7) 2451 (23.4)
 Sex
  Female 7705 (55.4) 2112 (61.6) 5593 (53.4)
  Male 6191 (44.6) 1316 (38.4) 4875 (46.6)
Health-related characteristics
 Asthma
  No 13,006 (93.6) 3208 (93.6) 9798 (93.6)
  Yes 890 (6.4) 220 (6.4) 670 (6.4)
 Body mass index
  ≤18.4 122 (0.9) 37 (1.1) 85 (0.8)
  18.5–24.9 4529 (32.6) 712 (20.8) 3817 (36.5)
  25.0–29.9 5498 (39.6) 1297 (37.8) 4201 (40.1)
  ≥30.0 3747 (27.0) 1382 (40.3) 2365 (22.6)
 Chronic obstructive lung diseasec
  No 13,173 (94.8) 3270 (95.4) 9903 (94.6)
  Yes 723 (5.2) 158 (4.6) 565 (5.4)
 Smoking status
  Current smoker 3603 (25.9) 1037 (30.3) 2566 (24.5)
  Former smoker 4500 (32.4) 808 (23.6) 3692 (35.3)
  Never smoker 5793 (41.7) 1583 (46.2) 4210 (40.2)
 Pack-years of smoking
  0 5854 (42.1) 1595 (46.5) 4259 (40.7)
  0.01–10.99 1913 (13.8) 555 (16.2) 1358 (13.0)
  11.00–24.74 1989 (14.3) 530 (15.5) 1459 (13.9)
  24.75–38.99 1947 (14.0) 356 (10.4) 1591 (15.2)
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All Participants Race
Black White
No. (%)a No. (%)a No. (%)a
  ≥39.00 1876 (13.5) 268 (7.8) 1608 (15.4)
  Unknown 317 (2.3) 124 (3.6) 193 (1.8)
aColumn percentages, unless otherwise noted.
b
Row percentages.
cOther than asthma.
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Table 2
Population-average estimates of FEV1, FVC, and FEV1/FVC at age 45 years, by race, sex, and baseline 
smoking status: the ARIC Study.
Characteristic FEV1, in ml FVC, in ml FEV1/FVC, %
Mean (95% CI)a Mean (95% CI)a Mean (95% CI)a
Black
 Female
  Current smoker 2565 (2510–2620) 3391 (3328–3454) 75.5 (74.5–76.4)
  Former smoker 2680 (2620–2739) 3499 (3434–3565) 76.6 (75.6–77.6)
  Never smoker 2695 (2643–2747) 3489 (3429–3548) 77.7 (76.9–78.5)
 Male
  Current smoker 2874 (2806–2943) 3841 (3765–3917) 74.5 (73.5–75.6)
  Former smoker 3052 (2982–3121) 3974 (3897–4051) 76.4 (75.4–77.4)
  Never smoker 3143 (3075–3211) 3956 (3876–4036) 79.1 (78.1–80.0)
White
 Female
  Current smoker 2732 (2696–2768) 3651 (3611–3692) 74.3 (73.7–74.8)
  Former smoker 3002 (2969–3035) 3908 (3871–3945) 77.0 (76.5–77.6)
  Never smoker 3079 (3050–3108) 3940 (3906–3973) 78.7 (78.3–79.2)
 Male
  Current smoker 3152 (3108–3195) 4372 (4324–4420) 72.6 (72.0–73.3)
  Former smoker 3503 (3465–3540) 4637 (4595–4679) 76.1 (75.5–76.6)
  Never smoker 3702 (3663–3741) 4751 (4706–4796) 78.7 (78.1–79.2)
aAdjusted for asthma history, body mass index, chronic obstructive lung disease other than asthma, height, follow-up time, and study center.
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Table 3
Population-averaged rateof change in FEV1, and FVC in ml/year, at ages 45, 60, and 75 years, generated using 
inverse-probability-weighted independence estimating equations conditioning-on-being-alive, stratified by 
race, sex, and visit-specific smoking status: the ARIC Study.
Characteristic Spirometry measure Age, in years
45 60 75
Mean (95% CI)a Mean (95% CI)a Mean (95% CI)a
Black
 Female
  Current smoker FEV1 −48.7 (−59.6, −37.8) −25.6 (−33.4,−17.8) −2.5 (−20.8, 15.8)
FVC −65.3 (−77.6,−53.1) −29.6 (−38.5, −20.7) 6.1 (−14.7, 26.8)
  Former smoker FEV1 −23.3 (−33.0, −13.6) −27.1 (−30.6, −23.6) −31.0 (−45.9, −16.0)
FVC −39.9 (−50.6,−29.1) −28.7 (−32.5, −25.0) −17.6 (−33.6,−1.5)
  Never smoker FEV1 −24.8 (−32.5,−17.1) −27.1 (−30.0, −24.1) −29.4 (−41.4,−17.3)
FVC −39.5 (−48.2, −30.8) −30.5 (−33.8,−27.1) −21.5 (−35.2, −7.8)
 Male
  Current smoker FEV1 −40.0 (−54.7, −25.2) −25.5 (−34.3, −16.7) − 11.0 (−34.6, 12.6)
FVC −60.6 (−78.1, −43.2) −28.1 (−40.0, −16.2) 4.4 (−24.5, 33.2)
  Former smoker FEV1 −24.8 (−38.7, −10.9) −37.2 (−42.8, −31.6) −49.6 (−71.3, −28.0)
FVC −43.2 (−59.2, −27.2) −35.2 (−41.4, −29.0) −27.2 (−51.9, −2.6)
  Never smoker FEV1 −29.5 (−43.9, −15.0) −40.4 (−47.7,−33.1) −51.2 (−73.3, −29.2)
FVC −45.0 (−62.9, −27.0) −39.1 (−48.2, −30.1) −33.3 (−59.5,−7.1)
White
 Female
  Current smoker FEV1 −53.1 (−60.6, −45.7) −22.0 (−26.5,−17.6) 9.1 (−4.1, 22.2)
FVC −58.9 (−67.2, −50.5) −26.8 (−31.9, −21.6) 5.3 (−10.0, 20.6)
  Former smoker FEV1 −37.4 (−44.0, −30.8) −33.2 (−35.4, −31.0) −29.1 (−39.2, −18.9)
FVC −45.9 (−53.0, −38.8) −38.3 (−40.7, −36.0) −30.7 (−41.6, −19.9)
  Never smoker FEV1 −38.5 (−43.2, −33.9) −32.8 (−34.4, −31.2) −27.1 (−34.3, −19.9)
FVC −44.8 (−50.3, −39.3) −39.4 (−41.4, −37.4) −34.0 (−42.5, −25.4)
 Male
  Current smoker FEV1 −67.0 (−76.6, −57.5) −29.0 (−35.9,−22.1) 9.0 (−7.7, 25.7)
FVC −79.8 (−89.7, −69.9) −28.8 (−36.1, −21.6) 22.1 (3.1, 41.2)
  Former smoker FEV1 −50.0 (−57.1, −42.9) −38.9 (−41.5, −36.3) −27.8 (−38.8, −16.8)
FVC −68.1 (−75.8, −60.5) −41.7 (−44.5, −38.9) −15.3 (−27.0,−3.6)
  Never smoker FEV1 −51.9 (−58.9, −44.8) −39.2 (−42.0, −36.4) −26.6 (−37.4, −15.7)
FVC −66.8 (−74.7, −59.0) −42.5 (−46.0,−39.1) −18.3 (−30.8, −5.8)
a
Estimated for participants aged 45–64 years at baseline and adjusted for baseline characteristics (age, height, study center) and time-varying 
characteristics collected at baseline and updated at visits 2 and 5 (asthma history, body mass index, chronic obstructive lung disease other than 
asthma, follow-up time).
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Table 4
Estimated annual declines in FEV1 and FVC, in ml/year, at ages 45, 60, and 75 years, generated using 
unweighted generalized estimating equations, stratified by race, sex, and smoking status: the ARIC Study.
Spirometry measure Age, in years
45 60 75
Mean (95% CI)a Mean (95% CI)a Mean (95% CI)a
Black
 Female
  Current smoker FEV1 −38.1 (−47.0, −29.1) −28.0 (−35.3, −20.8) −18.0 (−33.7, −2.4)
FVC −54.9 (−64.9, −44.9) −32.3 (−40.6, −24.0) −9.7 (−27.6, 8.2)
  Former smoker FEV1 −19.6 (−27.2,−12.0) −28.2 (−31.3, −25.0) −36.7 (−48.4,−25.1)
FVC −34.7 (−43.4, −25.9) −30.2 (−33.7, −26.7) −25.8 (−38.8, −12.7)
  Never smoker FEV1 −22.5 (−28.4, −16.5) −27.7 (−30.3, −25.0) −32.8 (−42.5, −23.2)
FVC −36.4 (−43.4, −29.5) −31.2 (−34.2, −28.2) −26.0 (−37.2, −14.8)
 Male
  Current smoker FEV1 −28.2 (−40.4, −16.0) −29.0 (−37.7, −20.3) −29.9 (−50.1, −9.7)
FVC −51.5 (−65.6, −37.5) −30.8 (−42.1, −19.5) −10.0 (−34.4, 14.3)
  Former smoker FEV1 −17.7 (−28.5,−6.8) −37.1 (−41.7, −32.6) −56.6 (−73.2, −39.9)
FVC −37.6 (−49.9, −25.2) −35.0 (−40.3, −29.7) −32.4 (−51.5,−13.2)
  Never smoker FEV1 −24.0 (−35.6, −12.4) −40.0 (−47.3, −32.8) −56.1 (−73.8, −38.5)
FVC −41.5 (−55.4, −27.7) −38.2 (−46.9, −29.5) −34.8 (−55.3, −14.4)
White
 Female
  Current smoker FEV1 −47.2 (−53.4, −41.0) −22.8 (−27.0, −18.5) 1.7 (−9.9, 13.3)
FVC −53.3 (−60.2, −46.4) −26.7 (−31.5, −21.9) −0.1 (−13.2, 13.0)
  Former smoker FEV1 −37.6 (−42.8, −32.5) −31.8 (−33.6, −30.0) −25.9 (−33.8,−18.1)
FVC −45.3 (−50.9, −39.7) −36.8 (−38.8, −34.9) −28.4 (−36.9, −19.9)
  Never smoker FEV1 −40.4 (−43.8,−37.1) −31.2 (−32.6, −29.8) −22.0 (−27.3, −16.6)
FVC −46.5 (−50.4, −42.7) −37.3 (−39.0, −35.7) −28.2 (−34.3, −22.0)
 Male
  Current smoker FEV1 −59.6 (−67.3, −51.9) −30.4 (−36.9, −23.8) − 1.2 (−16.0, 13.7)
FVC −72.5 (−80.9, −64.2) −30.5 (−37.6, −23.4) 11.6 (−5.0, 28.2)
  Former smoker FEV1 −47.6 (−53.0, −42.2) −37.0 (−39.2, −34.8) −26.4 (−34.7, −18.0)
FVC −64.3 (−70.2, −58.5) −40.4 (−42.9, −37.9) −16.5 (−25.7, −7.3)
  Never smoker FEV1 −51.6 (−56.9, −46.3) −37.6 (−40.1,−35.1) −23.6 (−31.9,−15.2)
FVC −65.3 (−71.3, −59.3) −40.6 (−43.7, −37.5) −16.0 (−25.7, −6.2)
a
Estimated for participants aged 45 years at baseline and adjusted for baseline characteristics (age, height, study center) and time-varying 
characteristics collected at baseline and updated at visits 2 and 5 (asthma history, body mass index, chronic obstructive lung disease other than 
asthma, follow-up time).
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